Plain-English translation of NCT07054489 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Heart Failure research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether genetic information can help predict which patients with mild heart failure will benefit most from beta-blockers. Beta-blockers are a common heart failure medication, but they work well for some people and not others, and can cause side effects like fatigue. The study will randomly assign participants to either receive the medication or a placebo (an inactive pill) and will use your genetic profile to help guide treatment decisions.
Currently, doctors don't have a good way to predict who will respond well to beta-blockers, so some patients take the medication without getting much benefit while experiencing unwanted side effects. This trial aims to use genetic testing to personalize treatment and help doctors decide which patients should receive this medication.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either take a beta-blocker medication or a placebo pill, and your dose will be gradually increased over time according to the study plan. Throughout the study, you'll have visits where your heart function and symptoms are monitored, and your genetic profile will be used to inform decisions about your treatment. The study will track how well the medication works for you based on both your response and your genetic information.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States